Business Wire

Hausfeld & Co LLP: Competition Appeal Tribunal to Hear Two Applications to Bring Collective Proceedings in Respect of Foreign Exchange Spot Trading Cartels

22.2.2021 11:00:00 EET | Business Wire | Press release

Share

From 12 to 16 July 2021, the Competition Appeal Tribunal (CAT) will consider whether to approve an application to bring collective proceedings (FX Claim UK) brought by Phillip Evans, the proposed class representative, and a former Inquiry Chair at the UK’s Competition and Markets Authority. The claim is brought against entities forming part of the following banking groups: Barclays, Citibank, The Royal Bank of Scotland/NatWest, JPMorgan, UBS and MUFG Bank.

Each of the banks has admitted infringements of EU competition law in relation to foreign exchange spot trading. Mr Evans’ proposed claim seeks compensation from the banks on behalf of proposed classes of persons who it is alleged have suffered losses due to the banks’ participation in those infringements.

The CAT has issued a legal notice concerning this hearing, which can be found here.

Mr Evans has instructed Hausfeld & Co LLP, a leading disputes-only specialist law firm, to conduct the claim. Hausfeld & Co LLP’s US affiliate, Hausfeld LLP, is co-lead counsel in the US FX class action, which recovered over $2.3 billion for those affected by FX misconduct in the US.

Mr Evans’ application asks the CAT to approve the claim as eligible to proceed as a collective proceeding on behalf of eligible entities and individuals and approve Mr Evans to act as the class representative.

The CAT will hear Mr Evans’ application at the same time as another application for permission to bring collective proceedings relating to the foreign exchange spot trading cartels, filed by Michael O’Higgins FX Class Representative Limited. As a result, the CAT may have to decide which of the proposed class representatives is the most suitable to act as the class representative. This would be the first time that the CAT has been asked to resolve a so-called ‘carriage dispute’ in relation to collective proceedings.

Any person with an interest in the two applications (including the proposed class members) may object to either or both of the applications or the authorisation of either or both of the proposed class representatives by writing to the CAT stating their reasons for objecting by 4pm on 4 May 2021. Those persons may also apply for permission to make written and/or oral submissions at the hearing in July by making such an application to the Tribunal, supported by reasons, by 4pm on 4 May 2021.

Phillip Evans commented: “It is in the interests of class members that questions of certification and carriage are resolved as soon as possible. I welcome the Tribunal’s decision to list the certification hearing for July 2021.”

Subject to any arrangements arising from the Covid-19 pandemic, the hearing will take place at the Competition Appeal Tribunal, Salisbury Square House, 8 Salisbury Square, London EC4Y 8AP. For information on how to take part in the Tribunal’s consideration of the two certification applications by submitting written observations or applying to be heard at the hearing in July, please visit www.fxclaimuk.com and view the CAT’s legal notice here.

Ends

Other languages

Access this press release in different languages:

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Matt Baldwin
Coast Communications
matt@coastcommunications.co.uk
+44 7930 439739

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye